NAUT · Nautilus Biotechnology Inc. Common Stock
View on chartInsiders & Stakes
| Mallick Parag Chief Scientist | ▲ Buy | Open Market | 20,493,392 Shares held | 5/12/2025 | View profile |
| Patel Sujal M CEO, President, and Secretary | ▲ Buy | Open Market | 10,366,721 Shares held | 3/4/2026 | View profile |
| PERCEPTIVE ADVISORS LLC Director | ▲ Buy | Open Market | 9,111,151 Shares held | 12/8/2021 | View profile |
| AH Equity Partners Bio II, L.L.C. | ▼ Sell | Open Market | 971,885 Shares held | 6/2/2026 | View profile |
| McIlwain Matthew S Director | ▲ Buy | Open Market | 459,075 Shares held | 11/15/2021 | View profile |
| Sankar Subramanian Senior VP, Product Development | ▲ Buy | Open Market | 91,250 Shares held | 9/27/2022 | View profile |
| Mowry Anna CFO and Treasurer | ▲ Buy | Open Market | 83,000 Shares held | 5/29/2025 | View profile |
| Murphy Matthew B. General Counsel | ▲ Buy | Open Market | 74,140 Shares held | 9/4/2025 | View profile |
| Matthew L. Posard Director | ▲ Buy | Open Market | 50,000 Shares held | 12/1/2021 | View profile |
| Weld Gwen E Chief People Officer | ▲ Buy | Open Market | 30,000 Shares held | 9/23/2022 | View profile |
| Suzuki Kentaro Chief Marketing Officer | ▲ Buy | Open Market | 4,000 Shares held | 11/6/2025 | View profile |
| Godwin Mary E. Senior VP, Operations | ▼ Sell | Open Market | 0 Shares held | 9/23/2024 | View profile |
Transaction History
| AH Equity Partners Bio II, L.L.C. | ▼ Sell | Open Market | 4,615,974 | $10.8M | 6/2/2026 |
| AH Equity Partners Bio II, L.L.C. | ▼ Sell | Open Market | 384,026 | $902K | 6/2/2026 |
| Patel Sujal M | ▲ Buy | Open Market | 25,000 | $65K | 3/4/2026 |
| Suzuki Kentaro | ▲ Buy | Open Market | 4,000 | $6K | 11/6/2025 |
| Patel Sujal M | ▲ Buy | Open Market | 83,500 | $57K | 9/8/2025 |
| Patel Sujal M | ▲ Buy | Open Market | 116,500 | $79K | 9/5/2025 |
| Murphy Matthew B. | ▲ Buy | Open Market | 20,000 | $13K | 9/4/2025 |
| Mowry Anna | ▲ Buy | Open Market | 15,000 | $11K | 5/29/2025 |
| Mallick Parag | ▲ Buy | Open Market | 1,500 | $1K | 5/12/2025 |
| Mallick Parag | ▲ Buy | Open Market | 12,000 | $9K | 5/8/2025 |
| Patel Sujal M | ▲ Buy | Open Market | 23,933 | $24K | 3/20/2025 |
| Patel Sujal M | ▲ Buy | Open Market | 53,300 | $53K | 3/19/2025 |
| Godwin Mary E. | ▲ Buy | Option Exercise | 47,031 | $22K | 9/23/2024 |
| Godwin Mary E. | ▼ Sell | Open Market | 47,031 | $135K | 9/23/2024 |
| Godwin Mary E. | ▲ Buy | Option Exercise | 35,000 | $16K | 9/17/2024 |
| Godwin Mary E. | ▼ Sell | Open Market | 35,000 | $100K | 9/17/2024 |
| Patel Sujal M | ▲ Buy | Open Market | 12,044 | $34K | 3/11/2024 |
| Patel Sujal M | ▲ Buy | Open Market | 2,430 | $7K | 3/8/2024 |
| Patel Sujal M | ▲ Buy | Open Market | 18,854 | $54K | 3/7/2024 |
| Patel Sujal M | ▲ Buy | Open Market | 9,267 | $25K | 3/6/2024 |
| Patel Sujal M | ▲ Buy | Open Market | 7,405 | $20K | 3/5/2024 |
| Sankar Subramanian | ▲ Buy | Open Market | 5,000 | $10K | 9/27/2022 |
| Sankar Subramanian | ▲ Buy | Open Market | 10,000 | $20K | 9/26/2022 |
| Weld Gwen E | ▲ Buy | Open Market | 30,000 | $61K | 9/23/2022 |
| Sankar Subramanian | ▲ Buy | Open Market | 35,000 | $75K | 9/16/2022 |
| Sankar Subramanian | ▲ Buy | Open Market | 40,000 | $88K | 9/15/2022 |
| Mowry Anna | ▲ Buy | Open Market | 17,500 | $40K | 8/19/2022 |
| Murphy Matthew B. | ▲ Buy | Open Market | 7,500 | $21K | 8/15/2022 |
| Murphy Matthew B. | ▲ Buy | Open Market | 2,500 | $7K | 8/12/2022 |
| Patel Sujal M | ▲ Buy | Open Market | 8,346 | $24K | 8/8/2022 |
| Patel Sujal M | ▲ Buy | Open Market | 41,654 | $122K | 8/5/2022 |
| Mowry Anna | ▲ Buy | Open Market | 5,500 | $15K | 6/27/2022 |
| Murphy Matthew B. | ▲ Buy | Grant | 10,000 | $33K | 5/12/2022 |
| Patel Sujal M | ▲ Buy | Open Market | 50,000 | $198K | 5/9/2022 |
| Patel Sujal M | ▲ Buy | Option Exercise | 100 | $1K | 3/4/2022 |
| Patel Sujal M | ▲ Buy | Open Market | 50,000 | $180K | 3/3/2022 |
| Mallick Parag | ▼ Sell | Gift | 210,000 | $0 | 12/21/2021 |
| PERCEPTIVE ADVISORS LLC | ▲ Buy | Open Market | 200,000 | $1.1M | 12/8/2021 |
| Patel Sujal M | ▲ Buy | Open Market | 88,022 | $416K | 12/1/2021 |
| Matthew L. Posard | ▲ Buy | Open Market | 10,000 | $45K | 12/1/2021 |
| Matthew L. Posard | ▲ Buy | Open Market | 10,000 | $45K | 12/1/2021 |
| Matthew L. Posard | ▲ Buy | Open Market | 10,000 | $44K | 12/1/2021 |
| Patel Sujal M | ▲ Buy | Open Market | 161,978 | $765K | 11/30/2021 |
| Matthew L. Posard | ▲ Buy | Open Market | 20,000 | $91K | 11/30/2021 |
| Mowry Anna | ▲ Buy | Open Market | 15,000 | $69K | 11/24/2021 |
| McIlwain Matthew S | ▲ Buy | Open Market | 100,000 | $530K | 11/15/2021 |
| McIlwain Matthew S | ▲ Buy | Open Market | 11,709 | $90K | 8/26/2021 |
| McIlwain Matthew S | ▲ Buy | Open Market | 11,693 | $90K | 8/25/2021 |
| McIlwain Matthew S | ▲ Buy | Open Market | 13,568 | $104K | 8/24/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Roth Capital initiates coverage on NAUT with $3.50 target
Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.
Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.